At this stage, our findings deliver an important message, suggesting that T-ALL treatment with DNA-damaging chemotherapeutic compounds could be efficiently personalised based on the level of EphB6 expression in T-ALL cells. This evidence concerns the gene EPHB6 and acute lymphoblastic leukemia.